Development of treatment strategy for CKD-MBD by multilateral mechanism of ethelcarcitrate hydrochloride - The DUET study

agoya University Graduate School of Medicine, Nephrology0 个研究点目标入组 120 人开始时间: 2018年1月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.patients who have been prescribed etelcalcetide before 2.bisphosphonate users within 24 weeks 3.primary hyperparathyroidism 4.undergoing parathyroidectomy or intervention therapy to parathyroid within 90 days before enrollment 5.scheduled parathyroidectomy, intervention therapy to parathyroid or kidney plantation 6. pregnant or breast feeding 7. patients who are deemed unsuitable by a physician, for instance cancer, severe infection and severe complication 8. patients who are prescribed Maxacalcitol, over 10[micro]gx3/week at obtainment of IC 9. patients who are prescribed Calcitriol, over 0.75[micro]gx3/week at obtainment of IC 10. patients who are prescribed other active VitD, over half of maximum dose at obtainment of IC 11. patients who are prescribed precipitated calcium carbonate, over 3g/day at obtainment of IC

发起方

agoya University Graduate School of Medicine, Nephrology